GEROPHARM has taken part in BIO International Convention 2014, an
international forum that took place on 23–26 June in San Diego.
It is a major conference on biotechnology which is held annually in
North America and has long become a popular venue for discussions on key
trends in the biotechnology market and key developments in the
therapeutic field. It was the fourth time that GEROPHARM participated in
Representing GEROPHARM were Lola Maksumova, Deputy Director-General
for Strategy, Artyom An, Head of the Business Development Department,
Darya Averyanova, Business Development Manager, and Vitaliy Latypov,
Head of the Genetic Engineering Laboratory of the R&D Centre.
Also, GEROPHARM was represented at the trade show as a co-exhibitor
with other Russian organisations. The Russian delegation consisted of
Sergey Tsyb, Deputy Minister of Industry and Trade of the Russian
Federation, Ludmila Ogorodova, Deputy Minister of Education and Science
of the Russian Federation, representatives of the Ministry of Economic
Development and the Ministry of Health of the Russian Federation,
pharmaceutical clusters and universities. GEROPHARM took part in the
grand formal opening of the Russian pavilion.
The company held BIO One-on-One Partnering meetings with
representatives of 25 international companies to discuss the prospects
of future-proof cooperation toward opening international markets for the
company’s products, conducting clinical studies, co-development
efforts, and licensing of foreign products in the Russian Federation and
the CIS. Furthermore, representatives of GEROPHARM participated in the
main events held under the BIO business programme, joining the
discussion of the key development trends in the global biosimilars
market, and paid a visit to Pfizer’s pharmaceutical plant.
BIO International Convention is a major forum for dialogue between the world’s leading biotechnology companies. For the domestic pharmaceutical industry, this is an opportunity to strengthen the role of Russia in the international market, to demonstrate its bioindustrial potential, to exchange experiences, and to build relationships based on mutually profitable cooperation.